Felicity Thomas

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

Pharmaceutical company, Nanomerics, and several companies that work with the pharmaceutical industry have been recognized by King Charles III for business achievements.

FDA has granted approval for the use of Novartis’ radioligand therapy, Lutathera, to treat pediatric patients with gastroenteropancreatic neuroendocrine tumors.

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews Dr. Krizia M. Karry, Global Head of Technical Marketing for BASF Pharma Solutions, on the topic of hot melt extrusion.

In this latest installment of the Europa Perspectives series, Alexander Natz, Secretary General at EUCOPE, delves into the European Commission’s new measures aimed at making lifecycle management more efficient across the European Union.

Our Future Health, a health research program in the UK, has welcomed Novartis as a new industry partner.

Plans to update the European Union’s variation framework have been finalized.

A revised regulatory variation framework should make lifecycle management more efficient in Europe.

More synthetic opioids have been placed under the strictest controls in the United Kingdom.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

The power of collaboration is a critically important for the bio/pharma industry.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

NICE has recommended the use of AbbVie's Tepkinly as a treatment option for eligible adults with diffuse large B-cell lymphoma.

ProductLife Group has announced its acquisition of Australian company Commercial Eyes.

The industry’s M&A activity is on the up and expected to continue to rise in 2024.

Agilent Technologies and Incyte have signed an agreement to collaborate on the development of companion diagnostics programs.

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews an esteemed panel of experts from IPEC Americas about excipient grades.

IMU Biosciences has secured £11.5 million in its Series A financing round.

Getinge has announced the inauguration of its new Global Centre of Excellence for Chemistry in the United Kingdom

The annual industry report of the Pharmapack Europe event suggests there will be significant innovation in inhaled pulmonary and intranasal drug delivery in 2024.

The acquisition marks a pivotal expansion for the company into the US market.

According to the Pharmapack Europe 2024 survey results, contract packaging will see growth over the coming 12 months.

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

Clarivate's Drugs to Watch report highlights 13 potential blockbuster drugs and gamechangers set to launch in 2024.

MHRA has granted a Clinical Trial Authorization to PharmaKure for its oral combined drug for the treatment of mild cognitive impairment.

Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide.